Press "Enter" to skip to content

XCyton develops diagnostic tool for life-threatening infections

Bangalore: XCyton Diagnostics has developed Syndrome Evaluation System (SES), a new diagnostic tool that would allow doctors to diagnose various life-threatening infections with just one test, in a few hours. The company claims its system is four times more accurate than conventional tests.

(From L-R) Latha Lakshman, Director and B V Ravi Kumar, Chairman and MD, both of XCyton Diagnostics; Kiran Mazumdar Shaw, Chairman and MD, Biocon; Prem Pavoor, Associate Director, FIL Capital Advisor (India); and Ketan Patel, Principal, Fidelity Bio-sciences

According to XCyton, SES allows for the immediate identification of multiple organisms including bacteria, viruses, fungi and parasites, in a specific test from a single sample. This process provides the clinician with a fast, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens.

Commercially available conventional tests like bacterial and fungal cultures, viral cultures or immunological tests take three to seven days to identify and detect the illness and thus is not of any help to the physician in decision making at that critical hour. With SES it is possible to have a report in seven hours, according to XCyton.

B V Ravi Kumar, founder, chairman and managing director of XCyton Diagnostics, says, “My belief that lives can be saved and disabilities can be prevented if the diagnosis is made early during the infection led to the creation of SES. It is inhuman not to apply available scientific knowledge to counter oppressive illnesses.”

According to XCyton, SES has created a paradigm shift from disease based sequential diagnosis to syndrome based diagnosis. In one sample, one test, all the probable causative agents that can cause a syndrome can be diagnosed, in a short duration of just seven hours, thus leading to early initiation of appropriate therapy and reduction of death and disability.

Kiran Mazumdar Shaw of Biocon, who has personally invested in XCyton, says, “XCyton’s syndrome evaluation diagnostics is a uniquely differentiated platform that will provide a novel way of rapidly diagnosing critical care infections and provide superior treatment outcomes. This is yet another approach to personalized medicine that is a very sought after space where XCyton is an early entrant from India.”

During the clinical trials, XCyton Diagnostics partnered with several institutes across the country. XCyton developed SES for AES (acute encephalitis syndrome), sepsis, antibiotic resistance and eye infections in collaboration with other institutes and the effort was supported by a financial loan from the Council for Scientific and Industrial Research (CSIR).

For AES, XCyton collaborated with the National Institute of Mental Health and Neuro Sciences (NIMHANS), for sepsis with the Centre for Cellular and Molecular Biology (CCMB), St John’s Medical College and Sankara Nethralaya and antibiotic resistance was done by XCyton. Eye infections were done in collaboration with CCMB, Sankara Nethralaya, LV Prasad Eye Institute and All India Institute of Medical Sciences (AIIMS).

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *